| Literature DB >> 26067607 |
Si-Jian Pan1, Shi-Kun Zhan2, Wei-Zhong Ji3, Yi-Xin Pan2, Wei Liu2, Dian-You Li2, Peng Huang2, Xiao-Xiao Zhang2, Chun-Yan Cao2, Jing Zhang2, Liu-Guan Bian1, Bomin Sun2, Qing-Fang Sun1.
Abstract
The ubiquitin-protein ligase E3C (UBE3C) belongs to the E3 ligase enzyme family and implicates in the ubiquitin-proteasome pathway, thus regulates physiological and cancer-related processes. Here, we investigated the expression and roles of UBE3C in glioma. We demonstrated that UBE3C was overexpressed in glioma tissues and cell lines. Inhibition of UBE3C expression in glioma cells significantly decreased cell migration and invasion in vitro. Mechanistically, we disclosed that UBE3C physically interacted with and ubiquitinated tumor suppressor gene annexin A7 (ANXA7), resulting in ubiquitination and degradation of ANXA7. Our results also revealed that increased UBE3C expression was accompanied by a reduction in ANXA7 protein expression in glioma tissues, but not ANXA7 mRNA. Importantly, the inhibition of ANXA7 expression in gliomas cells with UBE3C interference could rescue the cell invasion. Clinically, UBE3C overexpression significantly correlated with high-grade tumors (p < 0.05), poor overall survival, and early tumor recurrence. Thus, our data reveal that high UBE3C expression contributes to glioma progression by ubiquitination and degradation of ANXA7, and thus presents a novel and promising target for glioma therapy.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26067607 PMCID: PMC4464076 DOI: 10.1038/srep11066
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379